vinblastine

A novel prediction model was constructed based on seven RB-related signature genes for prognostic prediction in HCC patients. Targeted inhibition of CGREF1 may represent a potential strategy to improve therapeutic outcomes in HCC.

P3, N=1334, Completed, Takeda | Active, not recruiting --> Completed

The median number of therapeutic lines was four: 82% received chemotherapy (weekly vinblastine in 55%, vincristine/carboplatin regimen in 45%), 64% received MAPK pathway-targeted therapy, and 18% underwent radiotherapy...Conventional low-grade glioma chemotherapy constitutes the current treatment backbone, while MAPK pathway-targeted therapies show promising potential. Further studies and the establishment of an international registry are crucial to better characterize aggressive subtypes and optimize management strategies.

P4, N=124, Recruiting, Takeda | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028

P2, N=340, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2027 --> Nov 2026 | Trial primary completion date: Feb 2027 --> Nov 2026

P2, N=12, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 12

P1/2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

Furthermore, treatment with AVD (adriamycin/vinblastine/dacarbazine) in combination with brentuximab vedotin (BV) was initiated to achieve a complete metabolic response. Histopathologically, SV has a high proportion of HRS cells, with high CD30-positive and low EBER-positive rates. Therefore, CD30-targeted therapies such as BV may be preferable for SV, even in localized NS-HL patients, thereby improving patient prognosis.

This study establishes PHF19 as a potential prognostic indicator and immunotherapy target in PCPG, highlighting its immunomodulatory potential and the need to validate its therapeutic value functionally. Subsequent studies should focus on corroborating these results in broader cohorts and on probing the therapeutic prospects of targeting PHF19 in PCPG.

P1/2, N=63, Active, not recruiting, Centre Oscar Lambret | Trial primary completion date: May 2025 --> Dec 2025

P1/2, N=50, Recruiting, St. Justine's Hospital | Not yet recruiting --> Recruiting

Drug sensitivity analysis revealed that high DDR1 expression was associated with reduced sensitivity to methotrexate but increased sensitivity to vinblastine, doxorubicin, cisplatin, and docetaxel, with no significant difference observed for gefitinib. IHC of clinical samples confirmed DDR1 overexpression in 55.88% of NSCLC patients. Our study demonstrated that DDR1 promotes tumor progression and immune evasion and is frequently overexpressed in NSCLC patients, suggesting that DDR1 is a potential prognostic biomarker and therapeutic target.